

PharmLabs San Diego Certificate of Analysis



Sample **KTM Tablet - NO8BR11 - 416 - BlueRaz30**

Sample ID	SD250813-131 (121211)	Matrix	Edible
Tested for	Nolli-Homiezi		
Sampled	-	Received	Aug 13, 2025
Analyses executed	KTM	Reported	Aug 18, 2025
		Unit Mass (g)	5.183
		Num. of Servings	10
		Serving Size (g)	0.52

**KTM - Kratom**

Analyzed Aug 15, 2025 | Instrument HPLC VWD | Method SOP-KTM  
 The expanded Uncertainty of the Kratom analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
7-hydroxy Mitragynine (7HMG)	0.008	0.025	5.30	53.03	27.58	274.85
Mitragynine (MITG)	0.018	0.054	ND	ND	ND	ND
Speciogynine (SPEG)	0.007	0.02	ND	ND	ND	ND
Speciocilatine (SPCL)	0.004	0.011	ND	ND	ND	ND
Mitragynine Pseudoindoxyl (MITp)	0.235	0.713	NT	NT	NT	NT

UI Unidentified  
 ND Not Detected  
 N/A Not Applicable  
 NT Not Reported  
 LOD Limit of Detection  
 LOQ Limit of Quantification  
 <LOQ Detected  
 >ULOL Above upper limit of linearity  
 CFU/g Colony Forming Units per 1 gram  
 TNTC Too Numerous to Count



DCC license: C8-0000098-LIC  
 DEA license: RP0611043  
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
 Mon, 18 Aug 2025 11:13:07 -0700

PharmLabs San Diego | 3421 Hancock St., Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



\*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.

PharmLabs San Diego Certificate of Analysis



Sample **KTM Tablet - NO8MT11 - 416 - Mint30**

Sample ID	SD250813-127 (121207)	Matrix	Edible
Tested for	Nolli-Homiezi		
Sampled	-	Received	Aug 13, 2025
Analyses executed	KTM	Reported	Aug 18, 2025
		Unit Mass (g)	4.682
		Num. of Servings	9
		Serving Size (g)	0.52

**KTM - Kratom**

Analyzed Aug 15, 2025 | Instrument HPLC VWD | Method SOP-KTM  
 The expanded Uncertainty of the Kratom analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
7-hydroxy Mitragynine (7HMG)	0.008	0.025	5.06	50.65	26.34	237.14
Mitragynine (MITG)	0.018	0.054	ND	ND	ND	ND
Speciogynine (SPEG)	0.007	0.02	ND	ND	ND	ND
Speciocilatine (SPCL)	0.004	0.011	ND	ND	ND	ND
Mitragynine Pseudoindoxyl (MITp)	0.235	0.713	NT	NT	NT	NT

UI Unidentified  
 ND Not Detected  
 N/A Not Applicable  
 NT Not Reported  
 LOD Limit of Detection  
 LOQ Limit of Quantification  
 <LOQ Detected  
 >ULOL Above upper limit of linearity  
 CFU/g Colony Forming Units per 1 gram  
 TNTC Too Numerous to Count



DCC license: C8-0000098-LIC  
 DEA license: RP0611043  
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
 Mon, 18 Aug 2025 11:13:11 -0700

PharmLabs San Diego | 3421 Hancock St., Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



\*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.

PharmLabs San Diego Certificate of Analysis



Sample **KTM Tablet - NO8CT11 - 416 - Citrus30**

Sample ID	SD250813-129 (121209)	Matrix	Edible
Tested for	Nolli-Homiezi	Reported	Aug 18, 2025
Sampled	-	Received	Aug 13, 2025
Analyses executed	KTM	Unit Mass (g)	5.188
		Num. of Servings	10
		Serving Size (g)	0.52

**KTM - Kratom**

Analyzed Aug 15, 2025 | Instrument HPLC VWD | Method SOP-KTM  
 The expanded Uncertainty of the Kratom analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
7-hydroxy Mitragynine (7HMG)	0.008	0.025	5.30	52.95	27.53	274.70
Mitragynine (MITG)	0.018	0.054	ND	ND	ND	ND
Speciogynine (SPEG)	0.007	0.02	ND	ND	ND	ND
Speciocilatine (SPCL)	0.004	0.011	ND	ND	ND	ND
Mitragynine Pseudoindoxyl (MITp)	0.235	0.713	NT	NT	NT	NT

UI Unidentified  
 ND Not Detected  
 N/A Not Applicable  
 NT Not Reported  
 LOD Limit of Detection  
 LOQ Limit of Quantification  
 <LOQ Detected  
 >ULOL Above upper limit of linearity  
 CFU/g Colony Forming Units per 1 gram  
 TNTC Too Numerous to Count



DCC license: C8-0000098-LIC  
 DEA license: RP0611043  
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
 Mon, 18 Aug 2025 11:13:10 -0700

PharmLabs San Diego | 3421 Hancock St., Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



\*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.